Please login to the form below

Not currently logged in
Email:
Password:

Roche's pertuzumab fast-tracked by FDA for breast cancer

Drug is one of several medicines Roche expects will restore revenue growth in 2012

Roche and Genentech's pertuzumab for metastatic breast cancer has been accepted for fast-track review by the US Food and Drug Administration (FDA), with an action date set for June 8.

Pertuzumab is one of a new crop of medicines Roche expects will restore growth to its pharmaceutical sales in 2012 and beyond after a challenging period in 2011.

The drug has been filed for use in combination with Roche's Herceptin (trastuzumab) and docetaxel for patients with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.

The application is based on results from the pivotal phase III CLEOPATRA study, which demonstrated a 6.1 month improvement in median progression-free survival (PFS) for people who received the pertuzumab-based regimen compared to those on Herceptin and docetaxel alone.

Those who received the combination also experienced a 38 per cent reduction in the risk of their disease worsening or death, according to Roche.

Hal Barron, Roche's chief medical officer, said in a statement that new medicines are still needed for HER2-positive breast cancer.

"We have been researching HER2-positive breast cancer for more than 30 years, and we hope an expedited review will help us quickly bring another personalised medicine to people battling this aggressive disease," he added.

The market for breast cancer treatments is expected to reach around $10.8bn in seven major pharmaceutical markets by 2020, according to Decision Resources, despite a near-term dip as some of the top-selling products of the last few years lose patent protection.

Herceptin itself is due to lose patent protection within the next 10 years, but the addition of pertuzumab and a modified form of Herceptin (trastuzumab-DM1) to Roche's HER2-targetting franchise will actually boost sales by a $1bn or more, according to the market research firm.

8th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi’s philosophy is to go that extra mile. Look deeper. Discuss further.Study longer. Work harder.This focussed work ethic combined...

Latest intelligence

Acute leukaemia patients get new online information centre that will help them get the best possible care
A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational...
How to conduct a pharma content audit
A pharma content audit is essential for identifying whether your site delivers comprehensive, valuable information for the purpose of meeting the needs of your content marketing efforts....
14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....

Infographics